Wednesday, September 5, 2012

FDA Advisory Committe recommends approval for Tobramycin Inhlation Powder for Cystic Fibrosis

The Anti-Infective Drugs Advisory Committee (AIDAC) to the US Food and Drug Administration (FDA) today voted 13 to 1 that there was adequate evidence of efficacy and safety to support the use of tobramycin inhalation powder (TIP) for the management of cystic fibrosis (CF) patients whose lungs contain bacteria called Pseudomonas aeruginosa